期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 40, 期 1, 页码 221-226出版社
IOS PRESS
DOI: 10.3233/JAD-131850
关键词
Alzheimer's disease; dementia; institutionalization; longitudinal; nursing home; survival analysis
资金
- National Health and Medical Research Council
- Janssen-Cilag Pty Limited
- Eisai Pharmaceuticals
- Eli Lilly and Company
- GlaxoSmithKline
- H Lundbeck A/S
- Medivation Inc.
- Novartis Pharmaceuticals
- Nutricia
- Pfizer Inc.
- Prana Biotechnology Limited
- Sanofi-Aventis
- Tau Rx
- Voyager Pharmaceutical Corporation
- Wyeth Limited
- Servier
- Forest
- Takeda
- Buck Institute
- Baxter
- bioCSL
- Prana Biotechnology
- Merck Sharp and Dohme
- Lundbeck
- Prana
- Pfizer
- Novartis
Patients with dementia often require institutionalization when they can no longer care for themselves. The study examined demographic and clinical variables that predict the time until institutionalization in patients with dementia attending memory clinics. Of 970 patients recruited from nine memory clinics around Australia, 779 patients had dementia at baseline. Measures of dementia severity, cognition, functional ability, neuropsychiatric symptoms, caregiver burden, and medication use were completed for all patients. Patients were followed for three years. Overall, 197 (25.3%) of the patients with dementia were institutionalized within three years. Lower cognitive ability, lower functional ability, and more neuropsychiatric symptoms at baseline predicted a shorter time until institutionalization, as did use of antipsychotic medication. In addition, greater deterioration in cognitive ability, functional ability, and neuropsychiatric symptoms over the initial three months predicted a shorter time to institutionalization. The findings confirm that clinical features of dementia at baseline predict the time to institutionalization, as do greater changes in symptoms over three months independent of baseline levels.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据